Sildenafil: From the bench to the bedside

CMAJ. Canadian Medical Association Journal

Volumn 163, Issue 9, 2000, Pages 1171-1175

  Michelakis, E ^a   Tymchak, W ^a   Archer, S ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

CORPUS CAVERNOSUM; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMPOTENCE; MALE; PENIS ARTERY; PENIS ERECTION; REVIEW; RHINITIS; SMOOTH MUSCLE FIBER; VASODILATATION; VISUAL DISORDER;

EID: 0034739563     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association
2. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group
3. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
4. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction
5. Hemodynamic effects of sildenafil in men with severe coronary artery disease
6. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction. Onset Study Investigators
7. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase
8. Potassium channel diversity in vascular smooth muscle cells
9. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function